How Trazodone Works at Different Doses
Trazodone functions through dose-dependent receptor activity: at low doses (25-75 mg), it primarily acts as a sedative-hypnotic through potent 5-HT2A receptor antagonism and alpha-1 adrenergic blockade, while at higher antidepressant doses (150-300 mg), it additionally engages serotonin reuptake inhibition to achieve full antidepressant effects 1, 2, 3.
Mechanism of Action: The Dose-Dependent Story
Low-Dose Sleep Effects (25-75 mg)
At low doses used for sleep, trazodone works primarily through:
- 5-HT2A receptor antagonism (Ki = 35.6 nM) - This is the most potent action and blocks serotonin receptors that promote wakefulness 1
- Alpha-1 adrenergic receptor blockade (Ki = 153 nM) - This causes sedation but also explains the orthostatic hypotension risk 1
- Histamine receptor effects - Contributing to drowsiness 2
At these doses, the serotonin reuptake inhibition is minimal because the drug concentration isn't high enough to significantly occupy the serotonin transporter (Ki = 367 nM, which is much weaker than its receptor effects) 1.
High-Dose Antidepressant Effects (150-300 mg)
At therapeutic antidepressant doses, trazodone engages multiple mechanisms:
- Serotonin reuptake inhibition becomes clinically relevant at higher concentrations, enhancing serotonergic neurotransmission 1, 3
- Continued 5-HT2A antagonism - This dual action (blocking reuptake while antagonizing certain serotonin receptors) creates a unique profile that may reduce SSRI-type side effects like insomnia, anxiety, and sexual dysfunction 4
- 5-HT1A partial agonism (Ki = 118 nM) - May contribute to anxiolytic effects 1
The net result is enhanced serotonergic activity in pathways that improve mood, while simultaneously blocking receptors that cause agitation and sleep disruption 1, 2.
Clinical Translation
Why This Matters in Practice
For sleep (off-label use): The 2020 VA/DoD guidelines explicitly recommend against using trazodone for chronic insomnia, finding no differences in sleep efficiency versus placebo and concluding that "low-quality evidence supporting the efficacy of trazodone was outweighed by its adverse effect profile" 5. The 2017 AASM guideline similarly suggests clinicians not use trazodone for sleep onset or maintenance insomnia 6.
For depression: When used at proper antidepressant doses (150-300 mg), trazodone demonstrates efficacy comparable to tricyclics and SSRIs 3, 4. The 2008 AASM guidelines position it as a third-line option after benzodiazepine receptor agonists, specifically for cases with comorbid depression or treatment failures 7.
The Dosing Disconnect
A critical clinical pitfall: Low-dose trazodone (25-75 mg) used for sleep does NOT constitute adequate treatment for major depression 7. Conversely, the sedation at antidepressant doses (150-300 mg) can be managed by weighted bedtime dosing 8.
Pharmacokinetic Considerations
- Peak levels: 1 hour on empty stomach, 2 hours with food 1
- Half-life: 3-9 hours, favoring once-daily bedtime dosing for antidepressant use 8
- Metabolism: Extensive hepatic metabolism via CYP3A4 to active metabolite m-chlorophenylpiperazine (mCPP); <1% excreted unchanged 1
- Protein binding: 89-95% 1
Safety Profile
Common adverse effects include somnolence, dizziness, headache, and dry mouth 4, 9. Serious but rare risks include orthostatic hypotension (especially in elderly), priapism, QT prolongation, and cardiac arrhythmias 5, 1, 4.
The 2020 VA/DoD guidelines emphasize that trazodone's adverse effect profile outweighs benefits for insomnia treatment specifically 5, though it remains useful as an antidepressant with favorable tolerability compared to tricyclics (fewer anticholinergic effects, lower cardiotoxicity in overdose) 3, 4, 10.